We could not find any results for:
Make sure your spelling is correct or try broadening your search.
September 29, 2021 -- InvestorsHub NewsWire -- NetworkNewsWire Editorial Coverage: The fact that psychedelics is a nascent industry doesn’t seem to be discouraging savvy investors...
September 27, 2021 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: The emergence of psychedelic therapies as a popular investment a few years ago was mostly underscored by...
NetworkNewsWire Editorial Coverage: It’s early on in a burgeoning market, but there is certainly reason to be optimistic about the future of psychedelic medicines as a promising treatment...
July 27, 2021 -- InvestorsHub NewsWire -- via NetworkNewsWire Editorial Coverage: In July 2012, Congress created what is known as Breakthrough Therapy designation, a distinction that affords...
NetworkNewsWire Editorial Coverage: In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech...
NetworkNewsWire Editorial Coverage: Before government legislation brought the world of psychedelic drug compounds to a halt, promising research was being done in the space. As researchers and...
NetworkNewsWire Editorial Coverage: Before 1970, promising research was being conducted on the potential therapeutic effects of a broad category of psychedelic drug compounds, including substances...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
4 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
12 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
26 | 0 | 0 | 0.06 | 0.06 | 0.06 | 0 | 0 | CS |
52 | 0 | 0 | 0.06 | 0.065 | 0.01 | 15625 | 0.05054623 | CS |
156 | -0.17 | -73.9130434783 | 0.23 | 0.28 | 0.01 | 33255 | 0.11092013 | CS |
260 | -0.63 | -91.3043478261 | 0.69 | 1.2 | 0.01 | 85556 | 0.53334406 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions